BFM
MCRB icon

Boothbay Fund Management’s Seres Therapeutics MCRB Stock Holding History

Boothbay Fund Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-23
Closed -$214K – 1140
2020
Q2 		$214K Buy
+23
New +$2.02K 0.01% 784

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Boothbay Fund Management's MCRB Position: Q4 2022 in Review

Boothbay Fund Management sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 697 shares — an estimated $89K sold.

Boothbay Fund Management first reported a position in MCRB in Q2 2020 and held it in 8 quarters. The position peaked at $840K in Q1 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

  • Boothbay Fund Management reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 697 Seres Therapeutics shares in Q4 2022, an estimated $89K.
  • Boothbay Fund Management first reported a position in Seres Therapeutics in Q2 2020 and held it in 8 quarters.
  • Boothbay Fund Management's Seres Therapeutics position peaked at $840K in Q1 2021.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.